Pfizer confirmed late Friday that it will launch a company-wide cost-cutting program this year and next as sales of the drugmaker’s Covid vaccine and antiviral slide.
The announcement came as the US government and the drugmaker on Friday afternoon revised terms of their supply agreement for Paxlovid. Under the terms, the government is returning large numbers of doses that had been distributed around the country as access to the drug switches from an emergency, government run-effort to one run through the commercial markets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.